Home › Cervical Cancer › Louisiana › Shreveport
Cervical Cancer clinical trials in Shreveport, LA
3 studies for Cervical Cancer are looking for participants at sites in and around Shreveport (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Ocular Assessments in Patients Treated With Tivdak® in Recurrent or Metastatic Cervical Cancer
RecruitingPhase 4
- Trials365, LLC, Shreveport
- Willis Knighton Cancer Center, Shreveport
- Willis Knighton Physician Network - Hematology/Oncology, Shreveport
- and 3 more
A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)
RecruitingPhase 3
- TRIALS 365 ( Site 6008), Shreveport
A Trial of Robotic Versus Open Hysterectomy Surgery in Cervix Cancer
Recruiting
- Willis-Knighton Physician Network Gynecologic Oncology Associates, Shreveport
About Cervical Cancer
Cervical cancer starts in the cells of the cervix, which is the lower, narrow end of the uterus. Long-lasting HPV infection causes almost all cervical cancers.
More about Cervical Cancer on MedlinePlus
Cervical Cancer trials in other cities
- Houston, TX34 studies
- New York City, NY19 studies
- Nashville, TN19 studies
- Boston, MA18 studies
- Los Angeles, CA16 studies
- Arlington, VA16 studies
- San Antonio, TX14 studies
- Dallas, TX13 studies
- St. Louis, MO13 studies
- Orlando, FL12 studies
- Chicago, IL12 studies
- Columbus, OH11 studies
Other studies in Shreveport
- Breast Cancer8 studies
- Endometrial Cancer7 studies
- Ovarian Cancer7 studies
- Obesity7 studies
- Non-Small Cell Lung Cancer6 studies
- Cancer (all types)5 studies
- COPD5 studies
- Heart Failure4 studies
- Overweight4 studies
- Multiple Myeloma4 studies
- Cardiovascular Disease4 studies
- Steatotic Liver Disease3 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.